Jasper Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

JSPR$16.37-2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10–K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 30, 2026	JASPER THERAPEUTICS, INC.
	By:	/s/ Jeet Mahal
		Jeet Mahal Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Thomas G. Wiggans
Signature	Title	Date
/s/ Jeet Mahal	President, Chief Executive Officer and Director	March 30, 2026
Jeet Mahal	(Principal Executive Officer)
/s/ Herb Cross	Chief Financial Officer	March 30, 2026
Herb Cross	(Principal Accounting and Financial Officer)
/s/ Thomas G. Wiggans	Chairperson of the Board	March 30, 2026
/s/ Scott Brun, M.D.	Director	March 30, 2026
Scott Brun, M.D.
/s/ Vishal Kapoor	Director	March 30, 2026
Vishal Kapoor
/s/ Svetlana Lucas, Ph.D.	Director	March 30, 2026
Svetlana Lucas, Ph.D.
/s/ Christian W. Nolet	Director	March 30, 2026
Christian W. Nolet
/s/ Judith Shizuru, M.D., Ph.D.	Director	March 30, 2026
Judith Shizuru, M.D., Ph.D.
/s/ Kurt von Emster	Director	March 30, 2026
Kurt von Emster

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.